| Name | Title | Contact Details |
|---|
Mesoblast is a world leader in developing innovative cellular medicines. We have established what we believe is the industry`s most clinically advanced and diverse portfolio of cell-based products with five programs, two of which are partnered, in active Phase 3 clinical studies or Phase 3-ready, and four programs in Phase 2. All our clinical programs target significant, under-served therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions.
Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. Optibrium`s lead product, StarDrop™, is a comprehensive suite of integrated software with a highly visual and user-friendly interface. StarDrop™ enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the discovery process. The company`s new Augmented Chemistry™ products and services deliver ground-breaking artificial intelligence technologies that continuously learn from all available data to supplement your experience and skills. Founded in 2009, Optibrium is headquartered in Cambridge, UK with offices in Boston and San Francisco, USA. Optibrium continues to develop new products and research novel technologies to improve the efficiency and productivity of the drug discovery process. Optibrium works closely with its broad range of customers and collaborators that include leading global pharma, agrochemical and flavouring companies, biotech and academic groups.
Verona Pharma is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
At Inipharm, we`re building on novel insights and applying our chemistry expertise to develop therapies for patients with liver disease. Inipharm`s lead program is focused on small-molecules to target the activity of HSD17B13, a highly validated, genetically defined target for multiple severe liver and related diseases.
Coronado Biosciences is a Burlington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.